Femasys is trading at $1.60, down 7.78%, with no clear catalyst identified.

  • No confirmed company-specific announcement on October 16 explains the decline. The latest company news was an October 14 update that FemBloc FINALE trial enrollment sites had doubled to twelve.
  • The biotech sector is up 2.20%, so sector weakness does not explain the move.
  • Major market indices are mixed; none shows a same-direction move above 0.5%.